LivaNova PLC is a medical device company focused on the development and delivery of therapeutic solutions. The Company's segments include Cardiac Surgery, Cardiac Rhythm Management, Neuromodulation and Other. The Cardiac Surgery segment is engaged in the development, production and sale of cardiovascular surgery products. Cardiac Surgery products include oxygenators, heart-lung machines, autotransfusion, mechanical heart valves and tissue heart valves. The Cardiac Rhythm Management segment is engaged in the development, manufacturing and marketing of products for the diagnosis, treatment, and management of heart rhythm disorders and heart failure. Cardiac Rhythm Management products include high-voltage defibrillators Cardiac Resynchronization Therapy device (CRT-D) and low-voltage pacemakers. The Neuromodulation segment is engaged in the design, development and marketing of neuromodulation therapy for the treatment of drug-resistant epilepsy and treatment resistant depression.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Medical Equipment, Supplies & Distribution - NEC
- Sub-Industry: N/A
- Symbol: NASDAQ:LIVN
- CUSIP: N/A
- Web: www.livanova.com
- Market Cap: $3.02 billion
- Outstanding Shares: 48,186,000
- 50 Day Moving Avg: $61.08
- 200 Day Moving Avg: $53.78
- 52 Week Range: $40.83 - $63.21
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: 17.77
- P/E Growth: 1.35
- Annual Revenue: $1.21 billion
- Price / Sales: 2.46
- Book Value: $36.05 per share
- Price / Book: 1.72
- EBIDTA: $193.82 million
- Net Margins: -0.92%
- Return on Equity: 8.77%
- Return on Assets: 6.38%
- Debt-to-Equity Ratio: 0.04%
- Current Ratio: 2.04%
- Quick Ratio: 1.45%
- Average Volume: 549,011 shs.
- Beta: 0.62
- Short Ratio: 3.96
Frequently Asked Questions for LivaNova PLC (NASDAQ:LIVN)
What is LivaNova PLC's stock symbol?
LivaNova PLC trades on the NASDAQ under the ticker symbol "LIVN."
How were LivaNova PLC's earnings last quarter?
LivaNova PLC (NASDAQ:LIVN) released its earnings results on Wednesday, May, 3rd. The company reported $0.71 earnings per share for the quarter, beating analysts' consensus estimates of $0.68 by $0.03. The business earned $285.10 million during the quarter. LivaNova PLC had a negative net margin of 0.92% and a positive return on equity of 8.77%. View LivaNova PLC's Earnings History.
Where is LivaNova PLC's stock going? Where will LivaNova PLC's stock price be in 2017?
4 brokers have issued 12-month target prices for LivaNova PLC's stock. Their predictions range from $54.00 to $70.00. On average, they anticipate LivaNova PLC's stock price to reach $61.33 in the next twelve months. View Analyst Ratings for LivaNova PLC.
Are investors shorting LivaNova PLC?
LivaNova PLC saw a increase in short interest during the month of June. As of June 30th, there was short interest totalling 3,389,928 shares, an increase of 92.5% from the June 15th total of 1,761,418 shares. Based on an average trading volume of 1,245,778 shares, the days-to-cover ratio is currently 2.7 days. Approximately 7.8% of the company's shares are sold short.
Who are some of LivaNova PLC's key competitors?
Some companies that are related to LivaNova PLC include Hill-Rom Holdings (HRC), VWR Corp (VWR), Integra LifeSciences Holdings Corporation (IART), NuVasive (NUVA), ICU Medical (ICUI), Nevro Corp. (NVRO), Neogen Corporation (NEOG), Haemonetics Corporation (HAE), Inogen (INGN), Halyard Health (HYH), MiMedx Group (MDXG), CONMED Corporation (CNMD), K2M Group Holdings (KTWO), Asante Solutions (PUMP), Cardiovascular Systems (CSII), OraSure Technologies (OSUR), Orthofix International N.V. (OFIX) and Intersect ENT (XENT).
Who owns LivaNova PLC stock?
LivaNova PLC's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Fisher Asset Management LLC (0.33%), Waverton Investment Management Ltd (0.23%), Bank of Montreal Can (0.09%), Bollard Group LLC (0.07%), State Treasurer State of Michigan (0.04%) and Oregon Public Employees Retirement Fund (0.03%). Company insiders that own LivaNova PLC stock include Alfred J Novak, Daniel Jeffrey Moore, Hugh M Morrison, Jacques Gutedel, Sharon O'kane and Two SCA Equinox. View Institutional Ownership Trends for LivaNova PLC.
Who sold LivaNova PLC stock? Who is selling LivaNova PLC stock?
LivaNova PLC's stock was sold by a variety of institutional investors in the last quarter, including Capstone Asset Management Co.. Company insiders that have sold LivaNova PLC stock in the last year include Alfred J Novak, Daniel Jeffrey Moore, Hugh M Morrison, Jacques Gutedel and Two SCA Equinox. View Insider Buying and Selling for LivaNova PLC.
Who bought LivaNova PLC stock? Who is buying LivaNova PLC stock?
LivaNova PLC's stock was bought by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC, Waverton Investment Management Ltd, Bank of Montreal Can, Russell Investments Group Ltd., Eqis Capital Management Inc., Exane Derivatives, Oregon Public Employees Retirement Fund and LS Investment Advisors LLC. View Insider Buying and Selling for LivaNova PLC.
How do I buy LivaNova PLC stock?
Shares of LivaNova PLC can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is LivaNova PLC's stock price today?
MarketBeat Community Rating for LivaNova PLC (NASDAQ LIVN)MarketBeat's community ratings are surveys of what our community members think about LivaNova PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of LivaNova PLC stock can currently be purchased for approximately $61.84.
Consensus Ratings for LivaNova PLC (NASDAQ:LIVN) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||3 Hold Ratings, 1 Buy Rating|
|Consensus Rating:||Hold (Score: 2.25)|
|Consensus Price Target: ||$61.33 (0.82% downside)|
Analysts' Ratings History for LivaNova PLC (NASDAQ:LIVN)
(Data available from 7/25/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|3/10/2017||BTIG Research||Reiterated Rating||Hold||N/A|
|2/6/2017||Canaccord Genuity||Reiterated Rating||Hold||$54.00||N/A|
|8/31/2016||WBB Securities||Reiterated Rating||Hold||$60.00||N/A|
|8/5/2016||Piper Jaffray Companies||Reiterated Rating||Overweight||$59.00 -> $70.00||N/A|
|2/29/2016||Kepler Capital Markets||Boost Price Target||Hold||$63.00 -> $66.00||N/A|
|10/21/2015||Berenberg Bank||Initiated Coverage||Buy||$80.00||N/A|
Earnings History for LivaNova PLC (NASDAQ:LIVN)Earnings History by Quarter for LivaNova PLC (NASDAQ LIVN)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|3/1/2017||Q416||$0.79||$0.82||$301.45 million||$310.60 million||View||Listen|
|11/2/2016||Q316||$0.76||$0.78||$299.40 million||$295.30 million||View||N/A|
Earnings Estimates for LivaNova PLC (NASDAQ:LIVN)
Current Year EPS Consensus Estimate: $3.11 EPS
Next Year EPS Consensus Estimate: $3.48 EPS
Dividend History for LivaNova PLC (NASDAQ:LIVN)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for LivaNova PLC (NASDAQ:LIVN)
Insider Ownership Percentage: 0.28%Insider Trades by Quarter for LivaNova PLC (NASDAQ:LIVN)
Institutional Ownership Percentage: 73.01%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|7/17/2017||Daniel Jeffrey Moore||Director||Sell||1,000||$61.55||$61,550.00|| |
|6/15/2017||Daniel Jeffrey Moore||Director||Sell||1,000||$60.80||$60,800.00|| |
|5/23/2017||Sharon O'kane||Director||Buy||1,000||$58.58||$58,580.00|| |
|5/22/2017||Alfred J Novak||Director||Sell||1,000||$58.49||$58,490.00|| |
|5/5/2017||Hugh M Morrison||Director||Sell||3,215||$55.89||$179,686.35|| |
|4/17/2017||Daniel Jeffrey Moore||Director||Sell||1,000||$51.32||$51,320.00|| |
|3/15/2017||Daniel Jeffrey Moore||Director||Sell||1,000||$50.21||$50,210.00|| |
|9/22/2016||Two S.C.A. Equinox||Major Shareholder||Sell||185,000||$61.54||$11,384,900.00|| |
|9/21/2016||Two S.C.A. Equinox||Major Shareholder||Sell||391,379||$60.69||$23,752,791.51|| |
|9/16/2016||Two S.C.A. Equinox||Major Shareholder||Sell||75,213||$59.86||$4,502,250.18|| |
|9/13/2016||Two S.C.A. Equinox||Major Shareholder||Sell||25,408||$60.02||$1,524,988.16|| |
|9/8/2016||Two S.C.A. Equinox||Major Shareholder||Sell||208,000||$60.52||$12,588,160.00|| |
|8/9/2016||Jacques Gutedel||Insider||Sell||4,000||$60.52||$242,080.00|| |
|5/24/2016||Daniel Jeffrey Moore||Director||Sell||1,000||$50.07||$50,070.00|| |
|5/19/2016||Hugh M Morrison||Director||Sell||3,600||$48.00||$172,800.00|| |
|5/6/2016||Alfred J Novak||Director||Sell||4,000||$51.12||$204,480.00|| |
|4/15/2016||Daniel Jeffrey Moore||Director||Sell||1,000||$54.81||$54,810.00|| |
|3/15/2016||Daniel Jeffrey Moore||Director||Sell||1,000||$56.88||$56,880.00|| |
|2/16/2016||Daniel Jeffrey Moore||Director||Sell||1,000||$56.88||$56,880.00|| |
|1/15/2016||Daniel Jeffrey Moore||Director||Sell||1,000||$52.64||$52,640.00|| |
|12/15/2015||Daniel Jeffrey Moore||Director||Sell||2,500||$53.97||$134,925.00|| |
Headline Trends for LivaNova PLC (NASDAQ:LIVN)
Latest Headlines for LivaNova PLC (NASDAQ:LIVN)
|LivaNova PLC (LIVN) vs. CareFusion (CFN) Head to Head Contrast|
www.americanbankingnews.com - July 24 at 10:18 PM
|Insider Selling: LivaNova PLC (NASDAQ:LIVN) Director Sells 1,000 Shares of Stock|
www.americanbankingnews.com - July 18 at 1:44 PM
|LivaNova PLC (NASDAQ:LIVN) Short Interest Update|
www.americanbankingnews.com - July 16 at 7:23 AM
|ETFs with exposure to LivaNova Plc : July 4, 2017|
finance.yahoo.com - July 4 at 6:16 PM
|FDA Approves VNS Therapy Treatment for Drug-Resistant Epilepsy in Children as Young as Four Years Old|
finance.yahoo.com - June 30 at 1:05 AM
|LivaNova to Host Conference Call for Second Quarter 2017 Results|
finance.yahoo.com - June 27 at 6:28 PM
|LivaNova plc (LIVN) Receives FDA Approval for Expanded MRI Labeling|
www.streetinsider.com - June 21 at 4:06 PM
|VNS Therapy Receives FDA Approval for Expanded MRI Labeling|
finance.yahoo.com - June 21 at 4:06 PM
|Comparing Zimmer Biomet Holdings (ZBH) & LivaNova PLC (LIVN)|
www.americanbankingnews.com - June 18 at 6:04 PM
|ETFs with exposure to LivaNova Plc : June 16, 2017|
finance.yahoo.com - June 16 at 7:15 PM
|Insider Selling: LivaNova PLC (LIVN) Director Sells 1,000 Shares of Stock|
www.americanbankingnews.com - June 16 at 4:48 PM
|LivaNova Plc :LIVN-US: Earnings Analysis: Q1, 2017 By the Numbers : June 14, 2017|
finance.yahoo.com - June 14 at 10:31 AM
|LivaNova Appoints Keyna Skeffington as Senior Vice President and General Counsel|
finance.yahoo.com - June 12 at 9:40 AM
|LivaNova PLC (LIVN) and West Pharmaceutical Services (WST) Financial Comparison|
www.americanbankingnews.com - June 9 at 10:32 PM
|LivaNova PLC (LIVN) Director Sharon O'kane Purchases 1,000 Shares|
www.americanbankingnews.com - May 24 at 8:24 PM
|Alfred J. Novak Sells 1,000 Shares of LivaNova PLC (LIVN) Stock|
www.americanbankingnews.com - May 23 at 8:18 PM
|LivaNova (LIVN) Presents At Bank of America Merrill Lynch 2017 Health Care Conference - Slideshow|
seekingalpha.com - May 19 at 6:00 PM
|LivaNova PLC (LIVN) Director Hugh M. Morrison Sells 3,215 Shares|
www.americanbankingnews.com - May 9 at 4:37 PM
|LivaNova PLC to Present at the Bank of America Merrill Lynch and Jefferies Conferences|
finance.yahoo.com - May 9 at 12:00 PM
|LivaNova PLC (LIVN) Releases Earnings Results, Beats Estimates By $0.03 EPS|
www.americanbankingnews.com - May 5 at 11:53 PM
|LivaNova Announces New Data Reaffirming Value of Perceval for Aortic Valve Replacement in Aortic Stenosis Patients|
finance.yahoo.com - May 4 at 11:56 AM
|LivaNova PLC (LIVN) Getting Somewhat Negative Press Coverage, AlphaOne Reports|
www.americanbankingnews.com - May 4 at 11:17 AM
|LivaNova Reports First Quarter 2017 Results|
finance.yahoo.com - May 3 at 8:45 AM
|LivaNova posts 1Q profit|
finance.yahoo.com - May 3 at 8:45 AM
|Investor Network: Livanova PLC to Host Earnings Call|
finance.yahoo.com - May 3 at 8:45 AM
|LivaNova PLC (LIVN) Given News Impact Rating of -0.23|
www.americanbankingnews.com - April 30 at 7:52 AM
|LivaNova to Unveil New Data Further Demonstrating the Perceval Sutureless Valve is a Safe and Effective Aortic Valve Replacement for Patients|
finance.yahoo.com - April 28 at 7:14 PM
|LivaNova PLC (LIVN) Earning Very Favorable News Coverage, Analysis Finds|
www.americanbankingnews.com - April 27 at 10:04 AM
|LivaNova PLC (LIVN) Getting Somewhat Positive Press Coverage, Report Finds|
www.americanbankingnews.com - April 24 at 8:42 PM
|LivaNova PLC (LIVN) Receiving Positive Press Coverage, Report Finds|
www.americanbankingnews.com - April 21 at 10:27 PM
|LivaNova PLC (LIVN) Director Sells $51,320.00 in Stock|
www.americanbankingnews.com - April 19 at 8:23 PM
|LivaNova PLC (LIVN) Receiving Very Favorable Media Coverage, Study Finds|
www.americanbankingnews.com - April 17 at 9:14 AM
|LivaNova PLC (LIVN) Receiving Somewhat Favorable Media Coverage, Study Finds|
www.americanbankingnews.com - April 14 at 2:46 PM
|Short Interest in LivaNova PLC (LIVN) Decreases By 1.6%|
www.americanbankingnews.com - April 10 at 3:46 PM
|LivaNova Recognizes World Health Day Focus on Depression|
finance.yahoo.com - April 7 at 10:49 AM
|LivaNova PLC (LIVN) Receives Hold Rating from Canaccord Genuity|
www.americanbankingnews.com - April 2 at 11:06 AM
|LivaNova plc (LIVN) CFO to Depart|
www.streetinsider.com - April 2 at 10:14 AM
|INVESTOR ALERT: Goldberg Law PC Announces an Investigation of LivaNova PLC and Advises Investors with Losses to Contact the Firm|
finance.yahoo.com - April 1 at 12:09 PM
|LivaNova PLC Reiterates Full-Year 2017 Guidance|
uk.finance.yahoo.com - March 31 at 6:19 PM
|Glancy Prongay & Murray LLP Commences Investigation on Behalf of LivaNova PLC Investors|
finance.yahoo.com - March 31 at 6:19 PM
|LivaNova PLC Announces Chief Financial Officer Resignation|
uk.finance.yahoo.com - March 31 at 9:53 AM
|LIVANOVA PLC Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure, Financial State|
biz.yahoo.com - March 31 at 9:53 AM
|LivaNova to Host Conference Call for First Quarter 2017 Results|
uk.finance.yahoo.com - March 29 at 6:52 PM
|Camber Capital Management LLC Buys Allergan PLC, Myriad Genetics, Vertex Pharmaceuticals, Sells ...|
www.nasdaq.com - March 17 at 9:12 AM
|LIVANOVA PLC Financials|
finance.yahoo.com - March 7 at 6:03 PM
|LIVANOVA PLC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits|
biz.yahoo.com - March 1 at 11:13 AM
|LivaNova PLC - LIVN Intended Delisting and Cancellation of Ordinary Shares from London Stock Exchange|
www.businesswire.com - February 23 at 6:17 PM
|LivaNova PLC Announces Its Intent to Delist from London Stock Exchange|
uk.finance.yahoo.com - February 23 at 6:17 PM
|LivaNova Recognizes International Epilepsy Day|
uk.finance.yahoo.com - February 13 at 10:39 AM
|1:05 pm LivaNova announces a data presentation on the Perceval sutureless valve was unveiled at The Society of Thoracic Surgeons 53rd Annual Meeting; study found that AVR procedures conducted with Perceval resulted in low mortality & 'excel|
us.rd.yahoo.com - January 28 at 3:58 AM
LivaNova PLC (LIVN) Chart for Tuesday, July, 25, 2017